Cancer During Pregnancy in India: Diagnosis, Treatment & Hope

• Cancer in pregnancy is uncommon (roughly 1 in 1,000–1,500 pregnancies) but rising as women have babies later in life.
• Most cancers diagnosed in pregnancy can be treated without terminating the pregnancy; surgery is generally safe in the second trimester and many chemotherapy regimens are safe after the first trimester.
• Diagnosis uses pregnancy-safe tools first — ultrasound and MRI without contrast — and a biopsy should never be delayed because it gives the diagnosis treatment depends on.
• Breast and cervical cancers are the most common cancers found in pregnant women in India.
• Outcomes for mother and baby are far better than popular fear suggests, especially with care at an experienced multidisciplinary centre.
• Indian cancer hospitals (Tata Memorial, AIIMS, RGCI, Apollo, Manipal and other NCG centres) run coordinated cancer-in-pregnancy programmes, and schemes like Ayushman Bharat help with cost.

Cancer during pregnancy is rare — it affects roughly 1 in 1,000 to 1,500 pregnancies. But the number of women facing it each year is slowly rising, mainly because women are having children later, into the ages where cancer becomes more common. In India, women in cities now often have their first baby in their late 20s or 30s, which overlaps with rising cancer risk in those age bands. Higher rates of obesity and diabetes add to the trend, and routine pregnancy ultrasound sometimes picks up a cancer (for example an ovarian mass) by chance.

The cancers most often diagnosed during or just after pregnancy in Indian women are:

• Breast cancer — the most common, making up a large share of cases at major Indian centres.
• Cervical cancer — more prominent in Indian series than Western ones, reflecting India's high overall cervical cancer burden.
• Thyroid cancer — usually a slow-growing type where definitive treatment can often safely wait until after delivery.
• Lymphoma (especially Hodgkin lymphoma in young women), melanoma, ovarian cancer and others.

Diagnosing cancer in pregnancy means choosing tests that protect the baby while still giving doctors the answers they need. The good news is that the most useful tests are also the safest.

• Ultrasound is the workhorse. It uses no radiation, has no known risk to the baby, and gives detailed pictures of breast lumps, abdominal and pelvic masses, and lymph nodes. Breast ultrasound is the preferred first scan for a lump in pregnancy or breastfeeding.
• MRI without gadolinium contrast is the next choice when ultrasound is not enough. It uses no ionising radiation and is considered safe in pregnancy, especially in the second and third trimesters. Gadolinium contrast is avoided because it crosses the placenta and its long-term effects on the baby are uncertain.
• X-ray and CT involve radiation and are avoided when possible. When essential, a chest X-ray or a CT of an area far from the womb (like the chest or head) can be done with a lead shield over the abdomen, delivering a very low dose. CT of the abdomen or pelvis, and PET-CT, are generally avoided.

Treatment is timed around the baby's development. The first trimester is the most sensitive period, while the second and third trimesters are generally much safer for active cancer treatment.

First trimester (weeks 1–12). This is when the baby's organs are forming, so the risks from chemotherapy and radiation are highest. Surgery can be done if it truly cannot wait, but chemotherapy and radiation are avoided. For most cancers, treatment can be safely deferred to the second trimester. In a few very aggressive cancers that need immediate treatment, ending the pregnancy is one option that may be discussed — it is never automatic, and it is a deeply personal decision made with your oncology and maternal-fetal medicine team.

Second trimester (weeks 13–27). This is the safest window for most treatments. Surgery — including breast cancer surgery with sentinel lymph node biopsy — is well tolerated, and laparoscopic surgery is feasible up to about 24–28 weeks. Many chemotherapy regimens are safe now, because the baby is past organ formation. Drugs with established safety data in pregnancy include anthracyclines (doxorubicin, epirubicin), taxanes (paclitaxel), platinum agents (carboplatin, cisplatin), 5-fluorouracil and cyclophosphamide. A few specific drugs, such as methotrexate, are avoided throughout pregnancy.

Third trimester (weeks 28–delivery). Treatment continues on the same principles. Chemotherapy is usually stopped about 2–3 weeks before the planned delivery, so that the mother's and baby's blood counts recover before birth. Delivery is often planned for around 35–37 weeks to balance cancer care with the baby's maturity; if the baby must come earlier, steroids to mature the baby's lungs and NICU support are arranged. Any treatment that had to wait — radiation, targeted therapy, or hormone therapy — is then started after delivery.

Indian doctors follow a combination of national and international guidance. FOGSI (the Federation of Obstetric and Gynaecological Societies of India) provides India-specific direction that takes account of local resources, family decision-making and access. International ESMO (European Society for Medical Oncology) guidelines, widely used at Indian centres, give detailed, cancer-by-cancer treatment recommendations by trimester. The International Network on Cancer, Infertility and Pregnancy (INCIP) maintains a global registry that continually refines this evidence.

What these guidelines agree on is consistent and reassuring: get an accurate diagnosis without compromise, use treatments that are safe in pregnancy where the evidence supports them, and — most importantly — manage care through a coordinated multidisciplinary team rather than one isolated specialist.

Indian centres with established cancer-in-pregnancy programmes include Tata Memorial Hospital in Mumbai (the largest experience in the country), AIIMS Delhi, Rajiv Gandhi Cancer Institute, Apollo Cancer Centres, Manipal Hospitals, Fortis, Max Healthcare, HCG and Narayana Health, among other National Cancer Grid (NCG) centres. These teams bring together medical, surgical and radiation oncology, maternal-fetal medicine, neonatology, anaesthesia, pathology and counselling under one roof. If you live far from a metro, telemedicine consultations and self-referrals make it easier than ever to get an expert opinion — and because cancer in pregnancy is so individual, it is one situation where a referral to a high-risk pregnancy centre is genuinely worth the effort.

Treatment depends heavily on the type of cancer, its stage and how far along the pregnancy is. Here is how the most common ones are approached.

Breast cancer. Surgery (breast-conserving surgery or mastectomy, with sentinel node biopsy) is the cornerstone and is safe in the second and third trimesters. Anthracycline-based chemotherapy, with taxanes added later in pregnancy, is well established after the first trimester. Radiation is usually deferred until after delivery. HER2-targeted therapy (trastuzumab) and hormone therapy (tamoxifen) are not used during pregnancy because of effects on the baby. With stage-matched treatment, outcomes are similar to those of non-pregnant women of the same stage. For longer-term context, see breast cancer detection and treatment and breast cancer screening in India.

Cervical cancer. Management is highly individualised. Very early-stage disease may be managed with conisation and close monitoring, sometimes with a cervical stitch to protect the pregnancy. More advanced disease may be controlled with platinum chemotherapy until the baby is mature enough for delivery, or may need treatment that the pregnancy cannot continue around — these are decisions made carefully at experienced centres. Knowing your cervical cancer screening status, HPV history and HPV vaccination helps your team plan.

Thyroid cancer. Most thyroid cancers grow slowly enough that surgery can safely wait until the second trimester or until after delivery. Radioactive iodine is not given during pregnancy or breastfeeding. Outcomes are generally excellent. See thyroid cancer in Indian women for details.

Lymphoma and other cancers. Hodgkin and many non-Hodgkin lymphomas are highly treatable, and standard regimens (such as ABVD or CHOP) are used in the second and third trimesters with good results. Ovarian, melanoma and other cancers — including ovarian cancer and endometrial cancer — are managed with individualised plans built around the specific diagnosis and stage.

Decisions about when and how to deliver are made together by your obstetrician, oncologist, maternal-fetal medicine specialist and neonatologist. A few clear principles guide them:

• Finish planned chemotherapy before delivery, with a 2–3 week gap so blood counts recover for both mother and baby.
• Deliver at the earliest gestation that balances cancer care with the baby's maturity — often around 35–37 weeks for term-equivalent outcomes.
• Choose the mode of delivery on obstetric grounds, not cancer alone. A vaginal birth is usually fine. The main exception is invasive cervical cancer, where a caesarean is generally preferred.

Whether you can breastfeed depends on your treatment, not on the diagnosis alone.

• During active treatment, most chemotherapy drugs, targeted therapies and hormone therapies pass into breast milk and are not compatible with breastfeeding. Formula feeding during this time is a completely valid choice, and the bond with your baby is what matters most.
• After treatment ends, breastfeeding may be possible following an appropriate washout period (often 2–4 weeks, depending on the drug). Re-starting milk supply (relactation) is challenging but sometimes possible with a lactation consultant's help.
• After breast surgery, the treated breast may make little or no milk, but the unaffected breast usually works normally, and feeding from it is safe.

Carrying a baby and fighting cancer at the same time is an enormous emotional load — hope and fear in the same breath. Shock, anxiety, grief over the pregnancy you imagined, guilt (almost always misplaced), and fear about the future are all normal reactions to an extraordinary situation. They deserve support, not dismissal.

Practical help exists at every major NCG centre, where social workers and counsellors are familiar with cancer in pregnancy. Patient organisations offer peer support from women who have lived through it, including the V Care Foundation, the Cancer Patients Aid Association (CPAA) and the Indian Cancer Society. Free emotional-support helplines in India include:

• iCall — 9152987821
• Vandrevala Foundation — 1860-2662-345 (24x7)

Cancer-in-pregnancy care is generally more expensive than standard cancer care because it needs several specialty teams, high-risk maternity facilities and often a NICU. Total costs — covering diagnosis, treatment, delivery and postpartum care — typically range from about ₹2–15 lakh depending on the cancer and the centre, though this varies widely.

Several schemes ease the burden:

• Ayushman Bharat (PMJAY) covers up to ₹5 lakh per family per year, including cancer surgery, chemotherapy and hospitalisation.
• State schemes such as CMCHIS (Tamil Nadu), Aarogyasri (Telangana/AP), Mahatma Jyotiba Phule Jan Arogya Yojana (Maharashtra) and others provide similar cover.
• CGHS and ECHS cover central-government and defence families.
• Private health insurance covers cancer under standard mediclaim, with pregnancy care under maternity benefits if your policy includes it and waiting periods are complete.

This is the part families most need to hear: with proper treatment, outcomes for women diagnosed with cancer in pregnancy are generally similar to those for non-pregnant women with the same cancer at the same stage. Registries such as INCIP show that timing treatment safely within pregnancy — for instance, deferring first-trimester surgery to the second — does not usually worsen the mother's prognosis when the delay is short. Highly aggressive cancers, where every week counts, are the exception and need individual judgement.

For babies exposed to chemotherapy in the second and third trimesters, the evidence is reassuring. Rates of major birth defects are similar to the general population when chemotherapy is given after the first trimester. There is a higher chance of growth restriction and preterm birth, often because doctors deliberately deliver early to continue the mother's treatment. Long-term follow-up of these children shows similar growth, heart function, and cognitive and behavioural development compared with unexposed children.

Follow-up afterwards combines standard cancer survivorship care (surveillance for recurrence and management of treatment effects) with routine postpartum and gynaecological care. Many survivors go on to have more children in later years with planning and coordination; if more intensive treatment becomes necessary, fertility preservation for cancer survivors can be discussed. Children are followed with routine paediatric care plus reassurance checks. If you carry a strong family history, BRCA genetic testing and genetic counselling can guide future planning. The bottom line: the reality is far more hopeful than the popular fear — mother and baby can both thrive.

Pregnancy can mask the early signs of cancer, so do not assume a new symptom is "just pregnancy." See a doctor promptly if you notice any of the following — they usually have a harmless explanation, but they deserve a proper check:

• ESMO Clinical Practice Guidelines: Cancer, pregnancy and fertility preservation
• American College of Obstetricians and Gynecologists (ACOG): Guidelines for Diagnostic Imaging During Pregnancy and Lactation
• International Network on Cancer, Infertility and Pregnancy (INCIP)
• National Cancer Institute (NCI): Cancer Treatment During Pregnancy (PDQ)
• World Health Organization: Cervical cancer
• National Cancer Grid (NCG), India